Isthmus Partners LLC Sells 3,454 Shares of HCA Healthcare, Inc. $HCA

Isthmus Partners LLC lowered its holdings in HCA Healthcare, Inc. (NYSE:HCA) by 9.6% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 32,615 shares of the company’s stock after selling 3,454 shares during the period. HCA Healthcare accounts for approximately 1.6% of Isthmus Partners LLC’s investment portfolio, making the stock its 15th biggest holding. Isthmus Partners LLC’s holdings in HCA Healthcare were worth $15,435,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Palisade Asset Management LLC bought a new stake in HCA Healthcare in the third quarter valued at $26,000. Holos Integrated Wealth LLC purchased a new stake in shares of HCA Healthcare in the 4th quarter worth about $29,000. Ares Financial Consulting LLC purchased a new position in shares of HCA Healthcare during the fourth quarter valued at about $31,000. JPL Wealth Management LLC purchased a new stake in HCA Healthcare in the third quarter worth about $33,000. Finally, Aventura Private Wealth LLC purchased a new position in shares of HCA Healthcare during the 4th quarter worth approximately $34,000. Hedge funds and other institutional investors own 62.73% of the company’s stock.

HCA Healthcare Stock Performance

Shares of HCA Healthcare stock opened at $409.98 on Thursday. The company has a 50-day simple moving average of $398.58 and a two-hundred day simple moving average of $461.22. HCA Healthcare, Inc. has a 52-week low of $330.00 and a 52-week high of $556.52. The stock has a market capitalization of $90.95 billion, a PE ratio of 14.10, a price-to-earnings-growth ratio of 1.34 and a beta of 1.12.

HCA Healthcare (NYSE:HCA) last announced its quarterly earnings data on Friday, April 24th. The company reported $7.15 earnings per share for the quarter, missing analysts’ consensus estimates of $7.19 by ($0.04). The firm had revenue of $19.11 billion during the quarter, compared to analysts’ expectations of $19.09 billion. HCA Healthcare had a negative return on equity of 295.93% and a net margin of 8.89%.HCA Healthcare’s revenue was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $6.45 earnings per share. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. As a group, equities research analysts forecast that HCA Healthcare, Inc. will post 30.07 EPS for the current fiscal year.

HCA Healthcare Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 16th were given a $0.78 dividend. The ex-dividend date of this dividend was Tuesday, June 16th. This represents a $3.12 dividend on an annualized basis and a yield of 0.8%. HCA Healthcare’s payout ratio is 10.73%.

HCA Healthcare News Summary

Here are the key news stories impacting HCA Healthcare this week:

• Negative Sentiment: Barclays reaffirmed its equal weight rating but lowered its price target sharply to $427 from $496, signaling reduced expectations for HCA Healthcare’s near-term stock performance. Benzinga
• Negative Sentiment: Cantor Fitzgerald cut its price target on HCA Healthcare to $525 from $588, reflecting a more cautious stance even while keeping an overweight rating. Benzinga
• Neutral Sentiment: Options-market activity is drawing attention because traders appear to be positioning for a larger move in HCA Healthcare stock, but the headline does not confirm a clear directional catalyst. Zacks
• Neutral Sentiment: Commentary around HCA’s post-earnings valuation and hold/buy-sell debate adds uncertainty, but it mainly reinforces that investors are reassessing the stock after recent results. MSN
• Positive Sentiment: Longer-term bullish pieces highlight HCA Healthcare’s capacity-expansion strategy, ongoing revenue and profit growth, and sizable buyback capacity, which support the investment case over time. Zacks
• Positive Sentiment: Seeking Alpha argued that HCA remains attractively priced despite recent underperformance, citing improving fundamentals, rising revenue and profitability, and ongoing shareholder returns. Seeking Alpha

Analysts Set New Price Targets

Several brokerages recently weighed in on HCA. Leerink Partners reduced their price target on HCA Healthcare from $573.00 to $500.00 and set an “outperform” rating on the stock in a research note on Monday, April 27th. Oppenheimer dropped their target price on shares of HCA Healthcare from $540.00 to $520.00 and set an “outperform” rating on the stock in a report on Monday, April 27th. JPMorgan Chase & Co. lowered their price target on shares of HCA Healthcare from $535.00 to $490.00 and set a “neutral” rating for the company in a research report on Tuesday, May 19th. Jefferies Financial Group restated a “buy” rating and issued a $525.00 price objective on shares of HCA Healthcare in a report on Friday, April 24th. Finally, Stephens dropped their price target on HCA Healthcare from $560.00 to $530.00 and set an “overweight” rating on the stock in a research report on Monday, April 27th. Fourteen investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $497.14.

HCA Healthcare Profile

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.